Dupilumab in the treatment of severe uncontrolled chronic rhinosinusitis with nasal polyps ( CRSwNP ): A multicentric observational Phase IV real‐life study ( DUPIREAL )
Allergy · 2023-10 · 78 (10) · 2669-2683
DOI: 10.1111/all.15772 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Allergy, online erschienen am 26.05.2023. Verfasst von Eugenio De Corso und 27 weiteren Autor:innen. Beteiligte Einrichtung: Otorhinolaryngology Unit, A.Gemelli University Hospital Foundation IRCCS, Rome, Italy. Hauptthemen laut MEDLINE: Nasal Polyps, Rhinitis, Sinusitis. Die Arbeit wurde bisher 168-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
Chronic rhinosinusitis with nasal polyps (CRSwNP) is associated with significant morbidity and reduced health‐related quality of life. Findings from clinical trials have demonstrated the effectiveness of dupilumab in CRSwNP, although real‐world evidence is still limited.
Methods
This Phase IV real‐life, observational, multicenter study assessed the effectiveness and safety of dupilumab in patients with severe uncontrolled CRSwNP ( n = 648) over the first year of treatment. We collected data at baseline and after 1, 3, 6, 9, and 12 months of follow‐up. We focused on nasal polyps score (NPS), symptoms, and olfactory function. We stratified outcomes by comorbidities, previous surgery, and adherence to intranasal corticosteroids, and examined the success rates based on current guidelines, as well as potential predictors of response at each timepoint.
Results
We observed a significant decrease in NPS from a median value of 6 (IQR 5–6) at baseline to 1.0 (IQR 0.0–2.0) at 12 months ( p < .001), and a significant decrease in Sino‐Nasal Outcomes Test‐22 (SNOT‐22) from a median score of 58 (IQR 49–70) at baseline to 11 (IQR 6–21; p < .001) at 12 months. Sniffin' Sticks scores showed a significant increase over 12 months ( p < .001) compared to baseline. The results were unaffected by concomitant diseases, number of previous surgeries, and adherence to topical steroids, except for minor differences in rapidity of action. An excellent‐moderate response was observed in 96.9% of patients at 12 months based on EPOS 2020 criteria.
Conclusions
Our findings from this large‐scale real‐life study support the effectiveness of dupilumab as an add‐on therapy in patients with severe uncontrolled CRSwNP in reducing polyp size and improving the quality of life, severity of symptoms, nasal congestion, and smell.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Otorhinolaryngology Unit, A.Gemelli University Hospital Foundation IRCCS, Rome, Italy.
- Otorhinolaryngology Unit, Ospedale Bellaria Dip Chirurgie Specialistiche AUSL, Bologna, Italy.
- Otorhinolaryngology Unit, Head and Neck Department, IRCCS San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy.
- Department of Medical-Surgical Sciences and Advanced Technologies, E.N.T. Unit, P.O. "G. Rodolico", University of Catania, Catania, Italy.
- Department of Clinical, Surgical, Diagnostic and Pediatric Sciences, University of Pavia, Pavia, Italy.
- Department of Neurosciences, Otolaryngology Section, University of Padova, Padova, Italy.
ORCID-Profile: Eugenio De Corso, Ernesto Pasquini, Matteo Trimarchi, Ignazio La Mantia, Fabio Pagella, Giancarlo Ottaviano, Massimiliano Garzaro, Carlotta Pipolo, Sara Torretta, Veronica Seccia, Elena Cantone, Andrea Ciofalo, Daniela Lucidi, Gian Luca Fadda, Pia Clara Pafundi, Stefano Settimi, Claudio Montuori, Francesca Anastasi, Giulio Pagliuca, Angelo Ghidini, Carlo Cavaliere, Marianna Maffei, Francesco Bussu, Stefania Gallo, Frank Rikki Mauritz Canevari, Gaetano Paludetti, Jacopo Galli
Zitieren
APA
De Corso, E., Pasquini, E., Trimarchi, M., La Mantia, I., Pagella, F., Ottaviano, G., Garzaro, M., Pipolo, C., Torretta, S., Seccia, V., Cantone, E., Ciofalo, A., Lucidi, D., Fadda, G. L., Pafundi, P. C., Settimi, S., Montuori, C., Anastasi, F., Pagliuca, G., …, & Dupireal Italian Study Group (2023). Dupilumab in the treatment of severe uncontrolled chronic rhinosinusitis with nasal polyps ( CRSwNP ): A multicentric observational Phase IV real‐life study ( DUPIREAL ). Allergy, 78(10), 2669-2683. https://doi.org/10.1111/all.15772
Vancouver
De Corso E, Pasquini E, Trimarchi M, La Mantia I, Pagella F, Ottaviano G, et al. Dupilumab in the treatment of severe uncontrolled chronic rhinosinusitis with nasal polyps ( CRSwNP ): A multicentric observational Phase IV real‐life study ( DUPIREAL ). Allergy. 2023;78(10):2669-2683. doi:10.1111/all.15772
BibTeX
@article{DeCorso2023,
author = {De Corso, Eugenio and Pasquini, Ernesto and Trimarchi, Matteo and La Mantia, Ignazio and Pagella, Fabio and Ottaviano, Giancarlo and Garzaro, Massimiliano and Pipolo, Carlotta and Torretta, Sara and Seccia, Veronica and Cantone, Elena and Ciofalo, Andrea and Lucidi, Daniela and Fadda, Gian Luca and Pafundi, Pia Clara and Settimi, Stefano and Montuori, Claudio and Anastasi, Francesca and Pagliuca, Giulio and Ghidini, Angelo and Cavaliere, Carlo and Maffei, Marianna and Bussu, Francesco and Gallo, Stefania and Canevari, Frank Rikki Mauritz and Paludetti, Gaetano and Galli, Jacopo and Dupireal Italian Study Group, Dupireal Italian Study Group},
title = {Dupilumab in the treatment of severe uncontrolled chronic rhinosinusitis with nasal polyps ( CRSwNP ): A multicentric observational Phase IV real‐life study ( DUPIREAL )},
journal = {Allergy},
year = {2023},
volume = {78},
number = {10},
pages = {2669--2683},
doi = {10.1111/all.15772}
}
EUVIMED